Tumor-Infiltrating PD-1^hiCD8⁺-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers.

ABSTRACT:

Background

Stratification of patients who could benefit from immune checkpoint inhibitor (ICI) therapy is of much importance. PD-1^hiCD8⁺ T cells represent a newly identified and effective biomarker for ICI therapy response biomarker in lung cancer. Accurately quantifying these T cells using commonly available RNA sequencing (RNA-seq) data may extend their applications to more cancer types.

Method

We built a transcriptome signature of PD-1^hiCD8⁺ T cells from bulk RNA-seq and single-cell RNA-seq (scRNA-seq) data of tumor-infiltrating immune cells. The signature was validated by flow cytometry and in independent datasets. The clinical applications of the signature were explored in non-small-cell lung cancer, melanoma, gastric cancer,

SUBMITTER: Yang Z 

PROVIDER: S-EPMC8479164 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature